Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
| ▸ | MC4R | P32245 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69399 | 0.83 | KDM4E (0.55) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| SCHEMBL13837305 | 0.80 | ADORA3 (0.47) | HCAR2KDM4EPOLBTSHRLMNA | |
| SCHEMBL17449406 | 0.80 | ALDH1A1 (0.33) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| SCHEMBL31118151 | 0.79 | HCAR2 (0.46) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| SCHEMBL162262 | 0.79 | HCAR2 (0.46) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| Hydrochloric Acid SCHEMBL21752450 | 0.78 | ADORA3 (0.45) | HCAR2KDM4EPOLBTSHRLMNA | |
| SCHEMBL29497681 | 0.77 | HCAR2 (0.45) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| SCHEMBL9478482 | 0.77 | HCAR2 (0.45) | HCAR2KDM4ENAPRTALDH1A1POLB | |
| SCHEMBL17440722 | 0.75 | MRGPRX4 (0.43) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL28139894 | 0.75 | KDM4E (0.49) | KDM4EALDH1A1HPGDLMNAADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747247-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2026-05-27 | — | — | EP | disclosed |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| WO-2025215110-A1 | NEW AMIDE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS SOS1 INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-09-09 | — | — | US | disclosed |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | NOVARTIS AG (CH) | 2025-06-19 | — | — | US | disclosed |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-04-24 | — | — | US | disclosed |
| EP-4499631-A1 | PYRAZINE AMIDE DERIVATIVES | Novartis AG (CH) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025015420-A1 | NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-01-23 | — | — | WO | disclosed |
| CN-118591538-A | Pyrazinamide derivatives | 诺华股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| EP-3402799-B1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARM INC (US) | 2022-05-04 | — | — | EP | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| WO-2020030925-A1 | HETEROCYCLIC SUBSTITUTED UREAS, FOR USE AGAINST CANCER | ARTIOS PHARMA LIMITED (GB) | 2020-02-13 | — | — | WO | disclosed |
| EP-3402799-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-2753618-B1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017123884-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-07-20 | — | — | WO | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226129-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | HCAR2 387/4885KDM4E 1342/4885NAPRT 78/4885 |
| US-20250129027-A1 | FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF | FAAH, FAAH2, MGLL | HCAR2 64/4885KDM4E 1807/4885NAPRT 499/4885 |
| US-12410137-B2 | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof | FAAH, FAAH2, MGLL | HCAR2 64/4885KDM4E 1807/4885NAPRT 499/4885 |
| US-20250197376-A1 | PYRAZINE AMIDE DERIVATIVES | SIRT5, GLS2, ARG2 | HCAR2 911/4885KDM4E 1301/4885NAPRT 954/4885 |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, GTF3C5, EIF5B | HCAR2 3549/4885KDM4E 2235/4885NAPRT 153/4885 |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | HCAR2 980/4885KDM4E 2706/4885NAPRT 251/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | HCAR2 621/4885KDM4E 1675/4885NAPRT 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.